Table 4.
Difference of plaque extent per 1 SD increment in GlycA levels among individuals with plaque present (respective scores >0): the MACS-CVD2 study*,†,‡,§,‖
| Whole cohort (935) | HIV-infected men (589) | HIV-uninfected men (346) | |
|---|---|---|---|
| ln CAC score | |||
| Model 1 | 0.21 (0.07, 0.36) | 0.17 (−0.003, 0.34) | 0.30 (0.02, 0.57) |
| Model 2 | 0.21 (0.07, 0.36) | 0.19 (0.02, 0.37) | 0.24 (−0.07, 0.56) |
| Model 3 | 0.18 (0.02, 0.35) | 0.17 (−0.02, 0.36) | 0.21 (−0.16, 0.58) |
| Model 4 | 0.15 (−0.02, 0.31) | 0.11 (−0.09, 0.30) | 0.22 (−0.15, 0.59) |
| Model 5 | - | 0.10 (−0.10, 0.29) | - |
| p-for-interaction=0.29 | |||
| ln TP score | |||
| Model 1 | 0.19 (0.12, 0.26) | 0.12 (0.04, 0.21) | 0.30 (0.18, 0.42) |
| Model 2 | 0.15 (0.07, 0.22) | 0.09 (−0.002, 0.18) | 0.23 (0.11, 0.35) |
| Model 3 | 0.17 (0.09, 0.25) | 0.11 (0.01, 0.21) | 0.21 (0.07, 0.36) |
| Model 4 | 0.16 (0.08, 0.24) | 0.10 (0.002, 0.20) | 0.22 (0.07, 0.36) |
| Model 5 | - | 0.10 (−0.0003, 0.21) | - |
| p-for-interaction=0.003 | |||
| ln NCP score | |||
| Model 1 | 0.06 (−0.01, 0.13) | 0.02 (−0.06, 0.11) | 0.13 (0.01, 0.25) |
| Model 2 | 0.02 (−0.05, 0.09) | −0.01 (−0.10, 0.08) | 0.05 (−0.07, 0.17) |
| Model 3 | 0 (−0.08, 0.08) | −0.05 (−0.15, 0.06) | 0.05 (−0.09, 0.18) |
| Model 4 | 0 (−0.08, 0.07) | −0.03 (−0.13, 0.07) | 0.05 (−0.09, 0.19) |
| Model 5 | - | −0.03 (−0.14, 0.08) | - |
| p-for-interaction= 0.13 | |||
| ln MP score | |||
| Model 1 | 0.14 (0.05, 0.24) | 0.07 (−0.04, 0.18) | 0.28 (0.09, 0.46) |
| Model 2 | 0.12 (0.02, 0.22) | 0.06 (−0.06, 0.18) | 0.22 (0.002, 0.44) |
| Model 3 | 0.15 (0.03, 0.27) | 0.14 (−0.01, 0.28) | 0.25 (−0.03, 0.53) |
| Model 4 | 0.15 (0.02, 0.27) | 0.12 (−0.03, 0.27) | 0.25 (−0.05, 0.54) |
| Model 5 | - | 0.13 (−0.03, 0.29) | - |
| p-for-interaction=0.03 | |||
| ln CP score | |||
| Model 1 | 0.05 (−0.05, 0.14) | 0.03 (−0.09, 0.15) | 0.10 (−0.08, 0.27) |
| Model 2 | 0.01 (−0.08, 0.11) | −0.01 (−0.14, 0.12) | 0.07 (−0.11, 0.25) |
| Model 3 | 0.02 (−0.09, 0.13) | −0.02 (−0.17, 0.12) | 0.10 (−0.11, 0.30) |
| Model 4 | 0.02 (−0.09, 0.13) | −0.02 (−0.17, 0.13) | 0.12 (−0.09, 0.33) |
| Model 5 | - | −0.03 (−0.19, 0.13) | - |
| p-for-interaction=0.34 | |||
Table Abbreviations: CAC = coronary artery calcium; CP = calcified plaque; MP = mixed plaque; NCP = non-calcified plaque; TP = total plaque
SD for GlycA = 65.4 μmol/L
Associations are presented in beta-coefficients (95% CI) from linear regression models which were progressively adjusted as follows:
Model 1: adjusted for age, race, scanning center, pre/post 2001-cohort and HIV sero-status (in whole cohort analysis).
Model 2 (Main Model): Model 1 + systolic BP, BMI, physical activity level, use of hypertension medications, use of diabetes medications, fasting glucose, total and HDL cholesterol, use of lipid lowering medications, pack-years of tobacco smoking, eGFR and hepatitis C virus (HCV) -infection status.
Model 3: Model 2 + ln hsCRP, ln D-dimer, ln IL-6 and Fibrinogen.
Model 4: Model 3 + sCD163, sCD14, and ln CCL2.
Model 5: Model 4 + CD4 cell count, presence of detectable HIV RNA, nadir CD4 cell count, history of AIDS, duration of HAART, and use of protease inhibitors.
p-for-interaction adjusted for model 2
Bolded items are statistically significant (p <0.05)